---
figid: PMC9263770__atm-10-11-631-f9
figtitle: Yinzhihuang oral liquid protects against non-alcoholic steatohepatitis via
  modulation of the gut-liver axis in mice
organisms:
- Armoracia rusticana
- herbal medicine
- Scutellaria baicalensis
- Lycium barbarum
- Gardenia jasminoides
- Lonicera japonica
- Bacillus amyloliquefaciens
- Lactobacillus jensenii
- Patescibacteria group
- Homo sapiens
- Mus musculus
- Rattus norvegicus
- Macaca mulatta
- Danio rerio
- gut metagenome
- Homotherium serum
pmcid: PMC9263770
filename: atm-10-11-631-f9.jpg
figlink: /pmc/articles/PMC9263770/figure/f9/
number: F9
caption: Graphic abstract. Yinzhihuang oral liquid effectively alleviated steatosis,
  inflammation, and fibrosis, reduced serum aspartate transaminase and alanine transaminase,
  and improved glycolipid metabolism of NASH mouse. Meanwhile, YZH treatment significantly
  decreased the abundance of harmful bacteria, such as Mucispirillum, Helicobacter,
  and Desulfovibrionaceae. Mechanistically, YZH reduced gut leaky, decreased serum
  LPS, IL-6, and TNF-α levels, and increased IL10 in serum. In the liver, YZH decreased
  MCP-1, IL-1β and alleviated macrophage infiltration, especially pro-inflammatory
  macrophages. Moreover, YZH inhibited the canonical TLR4, MyD88, NFκB signaling pathway.
  NASH, non-alcoholic steatohepatitis; YZH, yinzhihuang; LPS, lipopolysaccharide;
  IL-6, interleukin-6; TNF-α, tumor necrosis factor alpha; MCP-1, monocyte chemoattractant
  protein 1; IL-1β, interleukin-1 beta; TLR4, toll-like receptor 4; MyD88, myeloid
  differentiation primary response 88; NFκB, nuclear factor kappa B.
papertitle: Yinzhihuang oral liquid protects against non-alcoholic steatohepatitis
  via modulation of the gut-liver axis in mice.
reftext: Shuyu Li, et al. Ann Transl Med. 2022 Jun;10(11):631.
year: '2022'
doi: 10.21037/atm-21-4809
journal_title: Annals of Translational Medicine
journal_nlm_ta: Ann Transl Med
publisher_name: AME Publishing Company
keywords: Yinzhihuang oral liquid | non-alcoholic steatohepatitis (NASH) | gut microbiota
  | gut-liver axis | nuclear factor kappa B (NFκB)
automl_pathway: 0.9498019
figid_alias: PMC9263770__F9
figtype: Figure
organisms_ner:
- Danio rerio
- Homo sapiens
- Rattus norvegicus
- Macaca mulatta
- Mus musculus
redirect_from: /figures/PMC9263770__F9
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9263770__atm-10-11-631-f9.html
  '@type': Dataset
  description: Graphic abstract. Yinzhihuang oral liquid effectively alleviated steatosis,
    inflammation, and fibrosis, reduced serum aspartate transaminase and alanine transaminase,
    and improved glycolipid metabolism of NASH mouse. Meanwhile, YZH treatment significantly
    decreased the abundance of harmful bacteria, such as Mucispirillum, Helicobacter,
    and Desulfovibrionaceae. Mechanistically, YZH reduced gut leaky, decreased serum
    LPS, IL-6, and TNF-α levels, and increased IL10 in serum. In the liver, YZH decreased
    MCP-1, IL-1β and alleviated macrophage infiltration, especially pro-inflammatory
    macrophages. Moreover, YZH inhibited the canonical TLR4, MyD88, NFκB signaling
    pathway. NASH, non-alcoholic steatohepatitis; YZH, yinzhihuang; LPS, lipopolysaccharide;
    IL-6, interleukin-6; TNF-α, tumor necrosis factor alpha; MCP-1, monocyte chemoattractant
    protein 1; IL-1β, interleukin-1 beta; TLR4, toll-like receptor 4; MyD88, myeloid
    differentiation primary response 88; NFκB, nuclear factor kappa B.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - il1b
  - irf5
  - il6
  - tnfrsfa
  - tnfb
  - il10
  - ora1
  - CCL2
  - IL1B
  - IRF5
  - IRF6
  - IL6
  - TNF
  - IL10
  - GPT
  - GOT1
  - SLC17A5
  - Ccl2
  - Il1b
  - Irf5
  - Il6
  - Tnf
  - Il10
  - Slc17a5
  - IL6ST
  - Mcpt1
  - Gusb
  - Tlr4
  - Gpt
  - Tmprss11d
---
